GSK/Valeant Potiga's Discontinuation Rate Could Be Its Undoing
This article was originally published in The Pink Sheet Daily
Executive Summary
Nearly one-third of clinical trial patients taking the antiepileptic had to stop due to adverse events.
You may also be interested in...
Potiga Whizzes Through Advisory Panel Review With Thorough Risk Management Plan
Despite urinary retention and a number of other concerning side effects, GlaxoSmithKline and Valeant's epilepsy drug ezogabine carries the day, based in part on a pledge to do a post-market observational safety study.
Potiga Whizzes Through Advisory Panel Review With Thorough Risk Management Plan
Despite urinary retention and a number of other concerning side effects, GlaxoSmithKline and Valeant's epilepsy drug ezogabine carries the day, based in part on a pledge to do a post-market observational safety study.
Valeant/GSK's Anti-Epileptic Potiga Faces Advisory Committee In Mid-August
High rate of adverse event-related dropouts in clinical trials could be a key focus of panel's discussion of ezogabine, also known as retigabine.